Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ACTRN12626001205325) titled 'A Phase 1, open-label single dose study to assess the pharmacokinetics and relative bioavailability of subcutaneously administered Claseprubart (DNTH103) across different injection sites and delivery methods in Healthy Volunteers' on Sept. 30.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Open (masking not used)
Assignment: Parallel
Type of endpoint: Pharmacokinetics
Primary Sponsor: Dianthus Therapeutics Inc
Condition:
Complement Mediated Diseases
Complement Mediated Diseases
Inflammatory and Immune System - Autoimmune diseases
Intervention: ...